Latest news
$400B AstraZeneca-Bristol Myers Squibb merger rumor draws market reaction - AxiosAxios · Fri, 07 Aug 2026 21:39:29 GMTThe Merger Paradox: Why Transformational Mergers Create Extraordinary Value and Frequently Fail - Pharmaceutical ExecutivePharmaceutical Executive · Fri, 07 Aug 2026 10:07:38 GMTYour Questions Answered: The Biggest Pharma Stories of the Week of August 3-7, 2026 - Pharmaceutical ExecutivePharmaceutical Executive · Fri, 07 Aug 2026 10:07:38 GMTMergers as Strategic Architecture: Rethinking How to Evaluate the AstraZeneca–BMS Rumors - Pharmaceutical ExecutivePharmaceutical Executive · Thu, 06 Aug 2026 10:02:44 GMTAstraZeneca denies media report of merger talks with BMS - medwatch.commedwatch.com · Thu, 06 Aug 2026 06:19:32 GMTPharma megamerger speculation collapses: No AstraZeneca-BMS talks - BioXconomyBioXconomy · Wed, 05 Aug 2026 16:29:21 GMTBeyond the Megamerger: How Rumored AstraZeneca–BMS Discussions Signal a New Era of Pharmaceutical Competition - Pharmaceutical ExecutivePharmaceutical Executive · Wed, 05 Aug 2026 15:17:36 GMTNo deal between AstraZeneca and BMS, senior source insists: Reuters - BioSpaceBioSpace · Wed, 05 Aug 2026 15:07:45 GMT